Publications in OpenAlex of which a co-author is affiliated to this organization
All publications | By field | By subfield
All publications [Next]
| Title | DOI |
|---|---|
| https://doi.org/10.1016/j.jnci.2013.07.001 | Gastric diffuse large B cell lymphoma presenting as paraneoplastic cerebellar degeneration: Case report and review of literature |
| https://doi.org/10.1200/jco.2014.32.15_suppl.tps659 | A phase III randomized trial of niraparib versus physician’s choice in previously treated, HER2-negative, germline-BRCA mutated breast cancer patients: Intergroup study EORTC-1307-BCG and BIG5-13. |
| https://doi.org/10.1200/jco.2018.36.5_suppl.180 | MHC-II expression to drive a unique pattern of adaptive resistance to antitumor immunity through receptor checkpoint engagement. |
| https://doi.org/10.1038/s41523-021-00301-0 | Evaluation of multiple transcriptomic gene risk signatures in male breast cancer |
| https://doi.org/10.1158/1078-0432.ccr-21-1317 | Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial |
| https://doi.org/10.1158/1538-7445.sabcs15-ot1-03-05 | Abstract OT1-03-05: A phase III, randomized, open label, multicenter, controlled trial of niraparib versus physician's choice in previously- treated, HER2 negative, germline BRCA mutation-positive breast cancer patients. An EORTC-BIG intergroup study (BRAVO study) |
| https://doi.org/10.1200/jco.2018.36.15_suppl.577 | Association between adaptive immune signature and outcome in HER2-positive breast cancer treated with trastuzumab and lapatinib in the NCCTG-N9831 (Alliance) and NeoALTTO trials. |
| https://doi.org/10.1093/annonc/mdz240.112 | ALEXANDRA/IMpassion030: A phase III study of standard adjuvant chemotherapy with or without atezolizumab in early stage triple negative breast cancer |
| https://doi.org/10.1200/jco.2022.40.16_suppl.tps607 | Adjuvant study of amcenestrant (SAR439859) versus tamoxifen for patients with hormone receptor-positive (HR+) early breast cancer (EBC), who have discontinued adjuvant aromatase inhibitor therapy due to treatment-related toxicity (AMEERA-6). |
| https://doi.org/10.20892/j.issn.2095-3941.2015.0099 | New generation of breast cancer clinical trials implementing molecular profiling |
| https://doi.org/10.1038/s41523-022-00430-0 | Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials |
| https://doi.org/10.1200/jco.2023.41.16_suppl.1019 | Clinico-molecular characteristics associated with outcomes in breast cancer patients treated with CDK4/6 inhibitors: Results from the AURORA Molecular Screening Initiative. |
| https://doi.org/10.1158/0008-5472.sabcs12-s4-6 | Abstract S4-6: An international Ki67 reproducibility study |
| https://doi.org/10.1371/journal.pone.0203346 | Feasibility of developing reliable gene expression modules from FFPE derived RNA profiled on Affymetrix arrays |
| https://doi.org/10.1002/jor.24700 | The effect of orthoses on the kinematics of the trapeziometacarpal, scaphotrapeziotrapezoidal, and radioscaphoid joints |
| https://doi.org/10.3390/cancers13071655 | Immune Checkpoint Blockade in HER2-Positive Breast Cancer: What Role in Early Disease Setting? |
| https://doi.org/10.1158/1538-7445.sabcs17-gs1-04 | Abstract GS1-04: Copy number aberration analysis to predict response to neoadjuvant anti-HER2 therapy: Results from the NeoALTTO phase III trial |
| https://doi.org/10.1093/jncics/pkaa058 | Validation of the NSABP/NRG Oncology 8-Gene Trastuzumab-benefit Signature in Alliance/NCCTG N9831 |
| https://doi.org/10.1158/1538-7445.sabcs15-p1-14-01 | Abstract P1-14-01: Phase II, randomized, parallel-cohort study of neoadjuvant buparlisib (BKM120) in combination with trastuzumab and paclitaxel in women with HER2-positive, PIK3CA mutant and PIK3CA wild-type primary breast cancer – NeoPHOEBE |
| https://doi.org/10.1200/jco.2022.40.16_suppl.518 | Impact of body mass index on treatment and outcomes in patients with early hormone receptor-positive breast cancer receiving endocrine therapy with or without palbociclib in the PALLAS trial. |
| https://doi.org/10.1016/j.ejso.2023.107081 | EORTC 1409 GITCG/ESSO 01 - A prospective colorectal liver metastasis database for borderline or initially unresectable diseases (CLIMB): Lessons learnt from real life. From paradigm to unmet need |
| https://doi.org/10.1200/jco.2022.40.16_suppl.509 | Prognostic and predictive implications of the intrinsic subtypes and gene expression signatures in early-stage HER2+ breast cancer: A pooled analysis of CALGB 40601, NeoALTTO, and NSABP B-41 trials. |
| https://doi.org/10.1158/1538-7445.sabcs22-ot1-04-01 | Abstract OT1-04-01: AMEERA-6: Phase 3 Study of Adjuvant Amcenestrant Versus Tamoxifen for Patients With Hormone Receptor-Positive Early Breast Cancer, Who Have Discontinued Adjuvant Aromatase Inhibitor Therapy Due to Treatment-related Toxicity |
| https://doi.org/10.1016/j.ejso.2024.108585 | A multidisciplinary team and patient perspective on omission of surgery after neoadjuvant systemic therapy for early breast cancer: A European Society of Surgical Oncology (ESSO) Research Academy survey |
| https://doi.org/10.1007/s40620-025-02280-y | 2023 European Kidney Forum: The future of kidney care – investing in green nephrology to meet the European Green Deal targets |
| https://doi.org/10.1093/annonc/mdn385 | Is risk of central nervous system (CNS) relapse related to adjuvant taxane treatment in node-positive breast cancer? Results of the CNS substudy in the intergroup phase III BIG 02-98 trial |
| https://doi.org/10.1016/b0-12-227235-8/00226-1 | INTERNATIONAL DAIRY FEDERATION |
| https://doi.org/10.4103/2278-330x.105896 | Challenges in launching multinational oncology clinical trials in India |
| https://doi.org/10.1093/annonc/mdz195 | Are we assuming too much with our statistical assumptions? Lessons learned from the ALTTO trial |
| https://doi.org/10.1039/c9mt00195f | Non-specific interference of cobalt with siderophore-dependent iron uptake pathways |
| https://doi.org/10.1016/j.annonc.2020.04.009 | Important considerations prior to elimination of breast cancer surgery after neoadjuvant systemic therapy: Listening to what our patients want |
| https://doi.org/10.1093/annonc/mdu034 | Factors affecting surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trial |
| https://doi.org/10.1200/jco.2015.33.15_suppl.516 | Tumor PIK3CA genotype and prognosis: A pooled analysis of 4,241 patients (pts) with early-stage breast cancer (BC). |
| https://doi.org/10.1200/jco.2014.32.3_suppl.524 | SoMore trial: Early metabolic response assessment of a sorafenib (SOR) and capecitabine (CAP) combination in chemorefractory metastatic colorectal cancer (mCRC). |
| https://doi.org/10.1038/s41416-021-01323-y | Patient-reported function, health-related quality of life, and symptoms in APHINITY: pertuzumab plus trastuzumab and chemotherapy in HER2-positive early breast cancer |
| https://doi.org/10.1158/1538-7445.sabcs14-s3-08 | Abstract S3-08: Randomized comparison of adjuvant tamoxifen (T) plus ovarian function suppression (OFS) versus tamoxifen in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Analysis of the SOFT trial |
| https://doi.org/10.1158/1538-7445.sabcs15-ot1-03-03 | Abstract OT1-03-03: FINESSE - An open, 3-cohort, phase II trial testing oral administration of lucitanib in patients with FGFR1-amplified or non-amplIfied oestrogeN rEceptor poSitive metaStatic breast cancEr |
| https://doi.org/10.1200/jco.2014.32.15_suppl.tps1134 | FINESSE: An open, three-cohort, phase II trial testing oral administration of lucitanib in patients with FGFR1-amplified or nonamplified estrogen receptor-positive metastatic breast cancer. |
| https://doi.org/10.1093/annonc/mdx138.004 | Tumor infiltrating lymphocytes in HER2-positive breast cancer patients treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of published randomized clinical trials |
| https://doi.org/10.1097/cad.0000000000000808 | Pharmacokinetics of pertuzumab administered concurrently with trastuzumab in Chinese patients with HER2-positive early breast cancer |
| https://doi.org/10.1158/1538-7445.sabcs20-pd3-01 | Abstract PD3-01: BluePrint performance in predicting pertuzumab benefit in genomically HER2-positive patients: A biomarker analysis of the APHINITY trial |
| https://doi.org/10.1158/1538-7445.sabcs15-ot1-03-21 | Abstract OT1-03-21: PALLAS: PAlbociclib Collaborative Adjuvant Study: A randomized phase 3 trial of palbociclib with adjuvant endocrine therapy versus endocrine therapy alone for HR+/HER2- early breast cancer |
| https://doi.org/10.1200/jco.2016.34.15_suppl.tps613 | LORELEI: A Phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib (GDC-0032) versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative, early-stage breast cancer. |
| https://doi.org/10.1200/jco.2014.32.15_suppl.647 | Quality of life (QOL) among patients (pts) with HER2+ breast cancer (bc) treated with adjuvant lapatinib and/or trastuzumab in the ALTTO study (BIG 2-06, Alliance N063D). |
| https://doi.org/10.1200/jco.2017.35.15_suppl.516 | Standard anthracycline-based vs. docetaxel-capecitabine in early breast cancer: Results from the chemotherapy randomization (R-C) of EORTC 10041/ BIG 3-04 MINDACT phase III trial. |
| https://doi.org/10.1016/j.annonc.2020.05.004 | Expanding the landscape of actionable genomic alterations in metastatic breast cancer: comprehensive genomic profiling for all? |
| https://doi.org/10.1136/esmoopen-2020-000979 | Prognostic role of distant disease-free interval from completion of adjuvant trastuzumab in HER2-positive early breast cancer: analysis from the ALTTO (BIG 2-06) trial |
| https://doi.org/10.1200/jco.2014.32.3_suppl.385 | Preoperative (preop) chemosensitivity testing as predictor of treatment benefit in adjuvant stage III colon cancer (CC): Interim analysis of the PEPITA study. |
| https://doi.org/10.1007/s12609-014-0178-4 | Tumour-Infiltrating Lymphocytes (TILs) in Breast Cancer: a Predictive or a Prognostic Marker? |
| https://doi.org/10.1016/j.ejso.2019.11.503 | Missed opportunities and challenges for surgical breast cancer research in the era of personalized cancer treatment |
| https://doi.org/10.1158/1538-7445.sabcs21-gs4-09 | Abstract GS4-09: Quality of life results from OlympiA: A phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)-adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER-2 negative early breast cancer |
| https://doi.org/10.1016/j.breast.2011.08.042 | Integrate: a new model in collaborative breast cancer research |
| https://doi.org/10.1200/jco.2013.31.15_suppl.610 | Progression-free survival (PFS) as surrogate endpoint for overall survival (OS) in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer (MBC): An individual patient data (IPD) analysis. |
| https://doi.org/10.1016/s1470-2045(19)30146-9 | Denosumab in early-stage breast cancer |
| https://doi.org/10.1200/jco.24.01080 | Further Optimizing Care of Patients With Operable Hormone Receptor–Sensitive Breast Cancer |
| https://doi.org/10.1097/ccm.0b013e3181921598 | Better translation from bench to bedside: Breakthroughs in the individualized treatment of cancer |
| https://doi.org/10.1016/j.pathophys.2016.10.003 | Food-added monosodium glutamate does not alter brain structure or antioxidant status |
| https://doi.org/10.1039/c8ob01044g | Influence of amino acid sequence in a peptidic Cu+-responsive luminescent probe inspired by the copper chaperone CusF |
| https://doi.org/10.1177/1758835919891608 | An RB-1 loss of function gene signature as a tool to predict response to neoadjuvant chemotherapy plus anti-HER2 agents: a substudy of the NeoALTTO trial (BIG 1-06) |
| https://doi.org/10.1016/s0959-8049(20)30560-8 | Nine-year survival outcome of neoadjuvant lapatinib with trastuzumab for HER2-positive breast cancer (NeoALTTO, BIG 1-06): final analysis of a multicentre, open-label, phase 3 randomised clinical trial. |
| https://doi.org/10.1158/1538-7445.sabcs21-p4-10-01 | Abstract P4-10-01: Quality of life and symptom severity in the PALLAS randomized trial of palbociclib with adjuvant endocrine therapy in early breast cancer (AFT-05) |
| https://doi.org/10.1038/s41416-022-01963-8 | Outcomes of patients with small and node-negative HER2-positive early breast cancer treated with adjuvant chemotherapy and anti-HER2 therapy—a sub-analysis of the ALTTO study |
| https://doi.org/10.1007/s10549-023-07159-9 | The impact of erythropoiesis-stimulating agents administration concomitantly with adjuvant anti-HER2 treatments on the outcomes of patients with early breast cancer: a sub-analysis of the ALTTO study |
| https://doi.org/10.1158/1538-7445.sabcs17-p5-18-01 | Abstract P5-18-01: Extended continuous vs intermittent adjuvant letrozole in postmenopausal women with lymph node-positive, early breast cancer (IBCSG 37-05/BIG 1-07 SOLE): Impact on patient-reported symptoms and quality of life |
| https://doi.org/10.1016/j.ejso.2023.107000 | A leap towards changing gender dynamics in oncology leadership – An ESSO-EYSAC initiative |
| https://doi.org/10.1007/s10549-025-07653-2 | Impact of adding palbociclib on treatment adherence to ongoing adjuvant endocrine treatment in the global randomized PALLAS randomized trial in patients with early breast cancer |
| https://doi.org/10.1200/jco.2025.43.16_suppl.e23009 | Facilitating meaningful patient involvement in the design and conduct of cancer research: The Breast International Group (BIG) patient partnership model. |
| https://doi.org/10.1002/jso.70045 | Clinical Use of Liquid Biopsy in Metastatic Breast Cancer—An ESSO‐EYSAC International Survey |
| https://doi.org/10.1016/j.annonc.2025.10.003 | Palbociclib with adjuvant endocrine therapy in early breast cancer: 5-year follow-up analysis of the global multicenter, open-label, randomized phase III PALLAS trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13) |
| https://doi.org/10.1097/cco.0b013e32832fc8b0 | Progress in tailoring adjuvant endocrine therapy for postmenopausal women with early breast cancer |
| https://doi.org/10.1078/0344-0338-00113 | Consequences of a National Mammography Screening Program on Diagnostic Procedures and Tumor Sizes in Breast Cancer. A Retrospective Study of 1540 Cases Diagnosed and Histologically Confirmed Between 1995 and 1997 |
| https://doi.org/10.1016/s0960-9776(09)70268-1 | Aiming at the target: improved adjuvant medical therapy |
| https://doi.org/10.1158/1538-7445.sabcs17-ot3-05-08 | Abstract OT3-05-08: PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase 3 trial of palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for HR+/HER2- early breast cancer |
| https://doi.org/10.1200/jco.2018.36.15_suppl.10067 | Impact of body mass index (BMI) and weight change after treatment in patients (pts) with HER2-positive (HER2+) early breast cancer (EBC): Secondary analysis of the ALTTO BIG 2-06 trial. |
| https://doi.org/10.1093/annonc/mdy272.281 | Lucitanib for the treatment of HR+ HER2- metastatic breast cancer (MBC) patients (pts): Results from the multicohort phase II FINESSE trial |
| https://doi.org/10.1200/jco.2019.37.15_suppl.1050 | Exploratory analysis of the effect of taselisib on downstream pathway modulation and correlation with tumor response in ER-positive/HER2-negative early-stage breast cancer from the LORELEI trial. |
| https://doi.org/10.1158/1538-7445.sabcs20-ps5-03 | Abstract PS5-03: Celtil score and long-term survival outcome in early stage HER2-positive (HER2+) breast cancer treated with anti-HER2-based chemotherapy: A correlative analysis of neoALTTO trial |
| https://doi.org/10.1016/s0923-7534(19)65666-8 | 21P Molecular Characterization of Early-Stage Her2-Overexpressing Breast Cancer (Her2+ Bc) Treated with Adjuvant Trastuzumab: Identification of Prognostic Groups |
| https://doi.org/10.1158/1538-7445.sabcs14-ot1-1-01 | Abstract OT1-1-01: LORELEI: A Phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib (GDC-0032) versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative, early stage breast cancer |
| https://doi.org/10.1093/annonc/mdv117.01 | Constitutively activated STAT3 is predictive for trastuzumab resistance in primary HER2 positive breast cancer |
| https://doi.org/10.1158/0008-5472.sabcs12-p6-07-06 | Abstract P6-07-06: Patterns of locoregional failure in the CALOR (Chemotheraphy as Adjuvant for Locally Recurrent Breast Cancer) Trial |
| https://doi.org/10.1200/jco.2015.33.15_suppl.613 | Lack of correlation of neoantigens arising from tumor somatic mutations with tumor infiltrating lymphocytes (TILs) or survival in HER2-positive breast cancer (HER2+ BC). |
| https://doi.org/10.1158/0008-5472.sabcs12-p1-07-08 | Abstract P1-07-08: Effect of sample preservation method and transportation duration on tumor gene expression profiling in breast cancer. |
| UJI PARAMETER SPASIAL OSEANOGRAFI POTENSI SUMBERDAYA LAUT | |
| https://doi.org/10.1158/1538-7445.sabcs16-p4-21-09 | Abstract P4-21-09: Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2 positive early breast cancer (BIG 1-06) |
| https://doi.org/10.1158/1538-7445.sabcs16-ot3-02-03 | Abstract OT3-02-03: Long-term follow-up of TEXT and SOFT trials of adjuvant endocrine therapies for premenopausal women with HR+ early breast cancer |
| https://doi.org/10.1200/jco.2014.32.15_suppl.1591 | A comparative analysis of the association between health expenditure and cancer survival in 168 countries. |
| https://doi.org/10.1093/annonc/mdx362.009 | Adjuvant anti-HER2 therapy, treatment-induced amenorrhea (TIA) and survival in premenopausal patients (pts) with HER2-positive (HER2+) early breast cancer (EBC): Analysis from the ALTTO trial (BIG 2-06) |
| https://doi.org/10.1007/978-3-319-48848-6_61 | Fertility Issues in Patients with Breast Cancer or Survivors |
| https://doi.org/10.1158/1538-7445.sabcs17-pd3-03 | Abstract PD3-03: Circulating tumor DNA in HER2 amplified breast cancer: A translational research substudy of the NeoALTTO phase 3 trial |
| https://doi.org/10.1158/1538-7445.sabcs17-pd5-04 | Abstract PD5-04: Ki67 changes and PEPI score in the LORELEI trial: A phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative early-stage breast cancer |
| https://doi.org/10.1158/1538-7445.sabcs17-p1-13-07 | Abstract P1-13-07: Incidence and management of diarrhea with adjuvant pertuzumab and trastuzumab in HER2-Positive breast cancer |
| https://doi.org/10.1158/1538-7445.sabcs18-p4-13-01 | Abstract P4-13-01: Endocrine treatment for hormone receptor-positive advanced breast cancer patients with endocrine-sensitive or endocrine-resistant disease: A systematic review and network meta-analysis |
| APLIKASI DATA INDERAJA DAN SIG UNTUK PERCEPATAN PENETAPAN BATAS ADMINISTRASI: Studi Kasus Provinsi Kalimantan Tengah, Indonesia | |
| https://doi.org/10.1200/jco.2019.37.15_suppl.11553 | Treatment completion and toxicity of trastuzumab or trastuzumab + lapatinib in older patients (pts): BIG 2-06; NCCTG N063D (Alliance). |
| https://doi.org/10.1158/1538-7445.sabcs20-gs4-11 | Abstract GS4-11: How low is low risk: MINDACT updated outcome and treatment benefit in patients considered clinical low risk and stratified by genomic signature, age and nodal status |
| https://doi.org/10.1200/jco.2021.39.15_suppl.524 | The prognostic performance of PREDICT+ in patients (pts) with HER2-positive (HER2+) early-stage breast cancer (EBC). |
| https://doi.org/10.1200/jco.2021.39.15_suppl.510 | Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab (P+T) in the APHINITY trial. |
| https://doi.org/10.1016/j.ejso.2022.01.002 | Standards in surgical training in advanced pelvic malignancy across Europe and beyond – A Snapshot analysis |
| https://doi.org/10.1158/1538-7445.sabcs21-gs1-07 | Abstract GS1-07: Adjuvant palbociclib in HR+/HER2- early breast cancer: Final results from 5,760 patients in the randomized phase III PALLAS trial |